Physician profile
Sanjay Chaube
NPI 1356458111
$3,335.74
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $482 · 2021: $633 · 2022: $644 · 2023: $190 · 2024: $41.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $519.03 | 2019-2022 | |
| Amgen INC. | $423.71 | 2019-2023 | Otezla, Repatha |
| Mylan Specialty L.P. | $395.64 | 2019-2023 | Yupelri |
| Abbvie INC. | $237.01 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $205.40 | 2019-2021 | |
| Allergan, INC. | $193.87 | 2019-2020 | |
| Lilly USA, LLC | $185.73 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $168.36 | 2019 | |
| Pfizer INC. | $153.84 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.30 | 2019-2024 | |
| Astellas Pharma US INC | $88.97 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $58.68 | 2019 | |
| Daiichi Sankyo INC. | $53.11 | 2021 | |
| Aurinia Pharma U.S., INC. | $50.94 | 2023 | Lupkynis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $42.64 | 2020-2022 | |
| Novo Nordisk INC | $37.02 | 2022 | |
| Nevro Corp. | $34.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.50 | 2021-2022 | |
| Sanofi Pasteur INC. | $29.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.28 | 2019 | |
| Janssen Biotech, INC. | $26.35 | 2019 | |
| Merz Pharmaceuticals, LLC | $21.81 | 2023 | Xeomin |
| Alnylam Pharmaceuticals INC. | $21.18 | 2023 | Onpattro |
| Tactile Systems Technology INC | $19.65 | 2022 | |
| Merck Sharp & Dohme LLC | $16.62 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.25 | 2019 | |
| Shire North American Group INC | $13.88 | 2019 | |
| Redhill Biopharma INC. | $13.84 | 2020 | |
| Dexcom, INC. | $13.14 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Chaube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.